1
|
Kryštůfek R, Šácha P, Starková J, Brynda J, Hradilek M, Tloušt'ová E, Grzymska J, Rut W, Boucher MJ, Drąg M, Majer P, Hájek M, Řezáčová P, Madhani HD, Craik CS, Konvalinka J. Re-emerging Aspartic Protease Targets: Examining Cryptococcus neoformans Major Aspartyl Peptidase 1 as a Target for Antifungal Drug Discovery. J Med Chem 2021; 64:6706-6719. [PMID: 34006103 PMCID: PMC8165695 DOI: 10.1021/acs.jmedchem.0c02177] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
![]()
Cryptococcosis is
an invasive infection that accounts for 15% of
AIDS-related fatalities. Still, treating cryptococcosis remains a
significant challenge due to the poor availability of effective antifungal
therapies and emergence of drug resistance. Interestingly, protease
inhibitor components of antiretroviral therapy regimens have shown
some clinical benefits in these opportunistic infections. We investigated
Major aspartyl peptidase 1 (May1), a secreted Cryptococcus
neoformans protease, as a possible target for the
development of drugs that act against both fungal and retroviral aspartyl
proteases. Here, we describe the biochemical characterization of May1,
present its high-resolution X-ray structure, and provide its substrate
specificity analysis. Through combinatorial screening of 11,520 compounds,
we identified a potent inhibitor of May1 and HIV protease. This dual-specificity
inhibitor exhibits antifungal activity in yeast culture, low cytotoxicity,
and low off-target activity against host proteases and could thus
serve as a lead compound for further development of May1 and HIV protease
inhibitors.
Collapse
Affiliation(s)
- Robin Kryštůfek
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic.,Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles UniversityHlavova 8, Prague 2 12843, Czech Republic
| | - Pavel Šácha
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles UniversityHlavova 8, Prague 2 12843, Czech Republic
| | - Jana Starková
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic
| | - Jiří Brynda
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic.,Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, Prague 4 14220, Czech Republic
| | - Martin Hradilek
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic
| | - Eva Tloušt'ová
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic
| | - Justyna Grzymska
- Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, Wroclaw 50-370, Poland
| | - Wioletta Rut
- Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, Wroclaw 50-370, Poland
| | - Michael J Boucher
- Department of Biochemistry & Biophysics, University of California, San Francisco, UCSF Genentech Hall, 600 16th St Rm N374, San Francisco, California 94158, United States
| | - Marcin Drąg
- Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, Wroclaw 50-370, Poland
| | - Pavel Majer
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic
| | - Miroslav Hájek
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic
| | - Pavlína Řezáčová
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic.,Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, Prague 4 14220, Czech Republic
| | - Hiten D Madhani
- Department of Biochemistry & Biophysics, University of California, San Francisco, UCSF Genentech Hall, 600 16th St Rm N374, San Francisco, California 94158, United States.,Chan-Zuckerberg Biohub, 499 Illinois Street, San Francisco, California 94158, United States
| | - Charles S Craik
- Department of Pharmaceutical Chemistry, University of California San Francisco, UCSF Genentech Hall, 600 16th St Rm S512, San Francisco, California 94158, United States
| | - Jan Konvalinka
- Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic.,Department of Biochemistry, Faculty of Science, Charles UniversityHlavova 8, Prague 2 12843, Czech Republic
| |
Collapse
|
2
|
Structure-Based Virtual Screening: Identification of a Novel NS2B-NS3 Protease Inhibitor with Potent Antiviral Activity against Zika and Dengue Viruses. Microorganisms 2021; 9:microorganisms9030545. [PMID: 33800763 PMCID: PMC8000814 DOI: 10.3390/microorganisms9030545] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 02/25/2021] [Accepted: 03/02/2021] [Indexed: 11/16/2022] Open
Abstract
Zika virus (ZIKV), which is associated with severe diseases in humans, has spread rapidly and globally since its emergence. ZIKV and dengue virus (DENV) are closely related, and antibody-dependent enhancement (ADE) of infection between cocirculating ZIKV and DENV may exacerbate disease. Despite these serious threats, there are currently no approved antiviral drugs against ZIKV and DENV. The NS2B-NS3 viral protease is an attractive antiviral target because it plays a pivotal role in polyprotein cleavage, which is required for viral replication. Thus, we sought to identify novel inhibitors of the NS2B-NS3 protease. To that aim, we performed structure-based virtual screening using 467,000 structurally diverse chemical compounds. Then, a fluorescence-based protease inhibition assay was used to test whether the selected candidates inhibited ZIKV protease activity. Among the 123 candidate inhibitors selected from virtual screening, compound 1 significantly inhibited ZIKV NS2B-NS3 protease activity in vitro. In addition, compound 1 effectively inhibited ZIKV and DENV infection of human cells. Molecular docking analysis suggested that compound 1 binds to the NS2B-NS3 protease of ZIKV and DENV. Thus, compound 1 could be used as a new therapeutic option for the development of more potent antiviral drugs against both ZIKV and DENV, reducing the risks of ADE.
Collapse
|
3
|
Cozens R, Bold G, Capraro HG, Fässler A, Mestan J, Lang M, Poncioni B, Stover D, Rösel J. Synthesis and Pharmacological Evaluation of CGP 57813 and CGP 61755, HIV-1 Protease Inhibitors from the Phe-c-Phe Peptidomimetic Class. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029600700602] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In this report we describe the enzyme inhibitory, antiviral and pharmacokinetic properties of CGP 57813 and CGP 61755, structural analogues of CGP 53437 that were synthesized in an attempt to obtain human immunodeficiency virus type 1 (HIV-1) protease inhibitors with improved selectivity and oral bioavailability. CGP 57813 inhibited HIV-1 protease with an IC50 of 11 nM (similar to CGP 53437). CGP 61755, on the other hand, was c.a. 10-fold more potent (IC50 = 1 nM; similar to saquinavir and indinavir). The selectivity profile of CGP 57813 was comparable to that of CGP 53437 while CGP 61755 clearly had improved selectivity for HIV-1 protease over human aspartic proteases. All three compounds had similar antiviral activity in HIV-1/MN infected MT-2 cells; ED50s were c.a. 5 nM and ED90s were 30 nM. Compared to CGP 53437, both CGP 57813 and CGP 61755 had markedly better bioavailability in mice after oral administration in a DMSO-hydroxypropyl-β-cyclodextrin formulation. However, when CGP 57813 was administered in a sesame oil-based formulation to either mice or dogs no useful plasma concentrations could be measured. In contrast, CGP 61755 was clearly bioavailable in dogs after oral administration of the compound in the same formulation; 1.2 g per dog resulted in a mean AUC0-8 h = 21.06 ± 3.53 μM.h, a mean Cmax = 4.8 ± 0.52 μM and compound was detectable for at least 8 h after administration. The potent antiviral activity of CGP 61755 together with improved selectivity and oral bioavailability holds promise for efficacy in AIDS therapy.
Collapse
Affiliation(s)
- R.M. Cozens
- Ciba, Pharmaceutical Division, Research Department Cancer and Infectious Diseases, CH 4002 Basel, Switzerland
| | - G. Bold
- Ciba, Pharmaceutical Division, Research Department Cancer and Infectious Diseases, CH 4002 Basel, Switzerland
| | - H-G. Capraro
- Ciba, Pharmaceutical Division, Research Department Cancer and Infectious Diseases, CH 4002 Basel, Switzerland
| | - A. Fässler
- Ciba, Pharmaceutical Division, Research Department Cancer and Infectious Diseases, CH 4002 Basel, Switzerland
| | - J. Mestan
- Ciba, Pharmaceutical Division, Research Department Cancer and Infectious Diseases, CH 4002 Basel, Switzerland
| | - M. Lang
- Ciba, Pharmaceutical Division, Research Department Cancer and Infectious Diseases, CH 4002 Basel, Switzerland
| | - B. Poncioni
- Ciba, Pharmaceutical Division, Research Department Cancer and Infectious Diseases, CH 4002 Basel, Switzerland
| | - D. Stover
- Ciba, Pharmaceutical Division, Research Department Cancer and Infectious Diseases, CH 4002 Basel, Switzerland
| | - J.L. Rösel
- Ciba, Pharmaceutical Division, Research Department Cancer and Infectious Diseases, CH 4002 Basel, Switzerland
| |
Collapse
|
4
|
Billich A, Scholz D, Charpiot B, Gstach H, Lehr P, Peichl P, Rosenwirth B. Potent and Orally Bioavailable HIV-1 Proteinase Inhibitors Containing the 2-aminobenzylstatine Moiety. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029500600507] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In order to design HIV proteinase inhibitors which combine antiviral potency in HIV-infected cells with good oral bioavailability, new derivatives of 2-aminobenzylstatine containing HIV-1 proteinase inhibitors were synthesized. Compounds showing the desired profile emerged from a series of modifications at the P3′ moiety of the parent inhibitor [1], and are characterized by the presence of hydroxy or methoxy substituents at the C-terminal benzylamide. The most potent congeners, compounds [15] and [19], were evaluated in more detail and proved inhibitory to HIV-1 replication in primary T4 lymphocytes with EC90 = 2.2 and 2.7 nM, respectively. They also exhibited adequate oral bioavailability in the range of [13] to 42% in mice and rats. Thus, further investigation of this type of HIV proteinase inhibitor seems warranted.
Collapse
Affiliation(s)
- A. Billich
- Sandoz Research Institute, Brunner Strasse 59, A-1235, Vienna, Austria
| | - D. Scholz
- Sandoz Research Institute, Brunner Strasse 59, A-1235, Vienna, Austria
| | - B. Charpiot
- Sandoz Research Institute, Brunner Strasse 59, A-1235, Vienna, Austria
| | - H. Gstach
- Sandoz Research Institute, Brunner Strasse 59, A-1235, Vienna, Austria
| | - P. Lehr
- Sandoz Research Institute, Brunner Strasse 59, A-1235, Vienna, Austria
| | - P. Peichl
- Sandoz Research Institute, Brunner Strasse 59, A-1235, Vienna, Austria
| | - B. Rosenwirth
- Sandoz Research Institute, Brunner Strasse 59, A-1235, Vienna, Austria
| |
Collapse
|
5
|
Kesteleyn B, Amssoms K, Schepens W, Hache G, Verschueren W, Van De Vreken W, Rombauts K, Meurs G, Sterkens P, Stoops B, Baert L, Austin N, Wegner J, Masungi C, Dierynck I, Lundgren S, Jönsson D, Parkes K, Kalayanov G, Wallberg H, Rosenquist A, Samuelsson B, Van Emelen K, Thuring JW. Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application. Bioorg Med Chem Lett 2012. [PMID: 23177258 DOI: 10.1016/j.bmcl.2012.10.095] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The design and synthesis of novel HIV-1 protease inhibitors (PIs) (1-22), which display high potency against HIV-1 wild-type and multi-PI-resistant HIV-mutant clinical isolates, is described. Lead optimization was initiated from compound 1, a Phe-Phe hydroxyethylene peptidomimetic PI, and was directed towards the discovery of new PIs suitable for a long-acting (LA) injectable drug application. Introducing a heterocyclic 6-methoxy-3-pyridinyl or a 6-(dimethylamino)-3-pyridinyl moiety (R(3)) at the para-position of the P1' benzyl fragment generated compounds with antiviral potency in the low single digit nanomolar range. Halogenation or alkylation of the metabolic hot spots on the various aromatic rings resulted in PIs with high stability against degradation in human liver microsomes and low plasma clearance in rats. Replacing the chromanolamine moiety (R(1)) in the P2 protease binding site by a cyclopentanolamine or a cyclohexanolamine derivative provided a series of high clearance PIs (16-22) with EC(50)s on wild-type HIV-1 in the range of 0.8-1.8 nM. PIs 18 and 22, formulated as nanosuspensions, showed gradual but sustained and complete release from the injection site over two months in rats, and were therefore identified as interesting candidates for a LA injectable drug application for treating HIV/AIDS.
Collapse
Affiliation(s)
- Bart Kesteleyn
- Janssen Infectious Diseases, A Division of Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Kaushik-Basu N, Basu A, Harris D. Peptide inhibition of HIV-1: current status and future potential. BioDrugs 2008; 22:161-75. [PMID: 18481899 DOI: 10.2165/00063030-200822030-00003] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
More than 2 decades of intensive research has focused on defining replication mechanisms of HIV type 1 (HIV-1), the etiologic agent of AIDS. The delineation of strategies for combating this viral infection has yielded many innovative approaches toward this end. HIV-1 is a lentivirus in the family retroviridae that is relatively small with regard to both structure and genome size, having a diploid RNA genome of approximately 9 kb, with only three major genes and several gene products resulting from alternate splicing and translational frameshifting. Most marketed drugs for treating AIDS are inhibitors of HIV-1 reverse transcriptase or protease enzymes, but new targets include the integrase enzyme, cell surface interactions that facilitate viral entry, and also virus particle maturation and assembly. The emergence of drug-resistant variants of HIV-1 has been the main impediment to successful treatment of AIDS. Thus, there is a pressing need to develop novel treatment strategies targeting multiple stages of the virus life-cycle. Research efforts aimed at developing successful means for combating HIV-1 infection have included development of peptide inhibitors of HIV-1. This article summarizes past and current endeavors in the development of peptides that inhibit replication of HIV-1 and the role of peptide inhibitors in the search for new anti-HIV drugs.
Collapse
Affiliation(s)
- Neerja Kaushik-Basu
- Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School, Newark, NJ 07103, USA.
| | | | | |
Collapse
|
7
|
|
8
|
Abstract
Considerable progress has been made in recent years in the field of drug development against HIV. Many different kinds of natural products, including coumarins, have been found to be active in anti-HIV models and are thus undergoing further investigation. This review demonstrates the variety of coumarins with unique mechanisms of action in the different stages of HIV replication. The discovery and development of coumarins as anti-HIV agents has expanded in the past two decades. Most of the studies have been focused on the inhibitory activity of reverse transcriptase, but anti-integrase and antiprotease activities were also described. The objective of this review is to evaluate data on coumarins’ potent activity with respect to the inhibition of HIV-reverse transcriptase, HIV-integrase or HIV-protease. Recent requirements for potential anti-HIV agents increasingly require adequate definition of the mechanism of action as well as definition of toxic effects and this also applies to natural as well as synthetic coumarins. Structural modification is a powerful tool to increase the potential of bioactive principles. By applying scientific expertise and modern scientific technology, new single compounds will assuredly be developed as potent anti-HIV candidates for world-class new drug development.
Collapse
Affiliation(s)
- Irena Kostova
- Department of Chemistry, Faculty of Pharmacy, 2 Dunav Str, Sofia 1000, Medical University, Bulgaria
| | - Jan Mojzis
- Department of Pharmacology, Medical Faculty, P.J. Safarik University, Tr. SNP 1 040 11 Kosice, Slovak Republic
| |
Collapse
|
9
|
|
10
|
Hobi R, Hübscher U, Neftel K, Alteri E, Poncioni B, Walker MR, Woods-Cook K, Schneider P, Lazdins JK. Anti-HIV-1 activity in vitro of ceftazidime degradation products. Antivir Chem Chemother 2001; 12:109-18. [PMID: 11527042 DOI: 10.1177/095632020101200204] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Cephalosporins in aqueous solutions generate degradation products that inhibit in vitro HIV-1 replication in cell lines, as well as in primary cells (lymphocytes and macrophages). This effect is observed at concentrations that do not interfere with the normal functions of these cells. Upon chromatographic fractionation of an aqueous solution of hydrolysed ceftazidime, a high molecular weight fraction (MW 8000) with antiviral activity was isolated. The exact chemical nature of the active component responsible for the anti-HIV activity in vitro appears to be complex and is currently unknown. Inhibition of HIV-1 reverse transcriptase and RNase H activity was observed, however, higher concentrations than those needed to inhibit HIV replication were required. The inhibitory action of the hydrolysed ceftazidime was manifested during the early phase of the HIV-1 life-cycle. Despite a lack of a direct effect of the CD4/gp120 interaction, HIV-1 mediated cell fusion was inhibited by the hydrolysed ceftazidime, suggesting that the active principle acts in a very early stage of the viral life-cycle.
Collapse
Affiliation(s)
- R Hobi
- Institute of Veterinary Biochemistry, University of Zürich-Irchel, Zürich, Switzerland.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Hamy F, Gelus N, Zeller M, Lazdins JL, Bailly C, Klimkait T. Blocking HIV replication by targeting Tat protein. CHEMISTRY & BIOLOGY 2000; 7:669-76. [PMID: 10980447 DOI: 10.1016/s1074-5521(00)00012-0] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND A rapid development of viral drug resistance poses a serious limitation in the current drug development programs against HIV. In turn, this obstacle forms the basis for new efforts, which utilize alternative viral targets. RESULTS By aiming at the Tat-driven process of HIV gene regulation, we discovered a new class of compounds as well as a novel target. The candidate compound acts on the one hand by classically inhibiting Tat/TAR complexation, however, without binding to nucleic acids. CONCLUSIONS Structure and molecular modeling/dynamics suggest that the stilbene derivative CGA137053 directly binds to Tat protein but not TAR RNA. As a completely new, second property, the compound also antagonizes a TAR-independent activity of free Tat protein by preventing the recently described upregulation of the HIV coreceptor CXCR4. With the stilbene CGA137053, we have identified a potent, double-hitting and chemically feasible Tat antagonist. The compound possesses high target specificity and low cytotoxicity, is not restricted to the Tat/TAR axis of HIV inhibition and highly active on HIV-infected, primary human cells.
Collapse
MESH Headings
- Amides/pharmacology
- Anti-HIV Agents/pharmacology
- CD4-Positive T-Lymphocytes
- Gene Expression Regulation, Viral/drug effects
- Gene Products, tat/antagonists & inhibitors
- Gene Products, tat/metabolism
- HIV Long Terminal Repeat/genetics
- HIV-1/drug effects
- HIV-1/genetics
- HIV-1/physiology
- HeLa Cells
- Humans
- Imidazoles/pharmacology
- Lymphocytes/virology
- Macrophages/virology
- Models, Molecular
- Nucleic Acid Conformation
- RNA, Viral/chemistry
- RNA, Viral/drug effects
- RNA, Viral/genetics
- Receptors, CXCR4/antagonists & inhibitors
- Receptors, CXCR4/physiology
- Recombinant Fusion Proteins/metabolism
- Transcriptional Activation/drug effects
- Virus Replication/drug effects
- beta-Galactosidase/metabolism
- tat Gene Products, Human Immunodeficiency Virus
Collapse
Affiliation(s)
- F Hamy
- Novartis Pharma Research, Basel, Switzerland
| | | | | | | | | | | |
Collapse
|
12
|
Sáez-Llorens X, Ramilo O. Early experience with protease inhibitors in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1998; 17:728-38. [PMID: 9726349 DOI: 10.1097/00006454-199808000-00013] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- X Sáez-Llorens
- Division of Infectious Diseases, Hospital del Niño, Panama City, Panama
| | | |
Collapse
|
13
|
Robinson WE. L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350). Antiviral Res 1998; 39:101-11. [PMID: 9806487 DOI: 10.1016/s0166-3542(98)00037-0] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Combinations of anti-human immunodeficiency virus (HIV) drugs, including reverse transcriptase inhibitors and protease inhibitors, have proven immensely potent in the therapy of acquired immune deficiency syndrome (AIDS). To determine whether HIV integrase is a suitable target for combination therapy, the ability of an HIV integrase inhibitor, L-chicoric acid, to work in combination with a protease inhibitor and Zidovudine was tested in vitro. The addition of L-chicoric acid to either Zidovudine or protease inhibitor improved upon the observed anti-HIV activity of either compound alone. When all three drugs were combined, the anti-HIV activity was substantially better than either of the three compounds alone or any combination of two inhibitors. Doses of both Zidovudine and protease inhibitor could be reduced by more than 33% for an equivalent anti-HIV effect if L-chicoric acid was added. The improved anti-HIV activity was observed with a tissue culture adapted strain of HIV (HIV(LAI)) and with limited passage clinical isolates of HIV (HIV(R19) and HIV(R45)). These data demonstrate that a first generation HIV integrase inhibitor, L-chicoric acid, is at least additive in combination with existing multi-drug regimens and suggest that HIV integrase will be an excellent target for combination therapy of HIV infection.
Collapse
Affiliation(s)
- W E Robinson
- Department of Pathology, University of California, Irvine, 92697-4800, USA.
| |
Collapse
|
14
|
Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-ela F, Varani G, Karn J, Klimkait T. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci U S A 1997; 94:3548-53. [PMID: 9108013 PMCID: PMC20476 DOI: 10.1073/pnas.94.8.3548] [Citation(s) in RCA: 204] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
One of the first steps in HIV gene expression is the recruitment of Tat protein to the transcription machinery after its binding to the RNA response element TAR. Starting from a pool of 3.2 x 10(6) individual chemical entities, we were able to select a hybrid peptoid/peptide oligomer of 9 residues (CGP64222) that was able to block the formation of the Tat/TAR RNA complex in vitro at nanomolar concentrations. NMR studies demonstrated that the compound binds similarly to polypeptides derived from the Tat protein and induces a conformational change in TAR RNA at the Tat-binding site. In addition, 10-30 microM CGP64222 specifically inhibited Tat activity in a cellular Tat-dependent transactivation assay [fusion-induced gene stimulation (FIGS) assay] and blocked HIV-1 replication in primary human lymphocytes. By contrast, peptides of a comparable size and side-chain composition inhibited cell fusion in the FIGS assay and only partially inhibited HIV-1 replication in primary human lymphocytes. Thus, we have discovered a compound, CGP64222, that specifically inhibits the Tat/TAR RNA interaction, both in vitro and in vivo.
Collapse
Affiliation(s)
- F Hamy
- Novartis, Ltd., Pharmaceuticals, Pharma Research, Basle, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Lazdins JK, Walker JK, Cozens RM, Flesch G, Czendlik C, Howald H, Kremers W, Alteri E. Ex Vivo anti-HIV Activity of Human Serum Obtained from Normal Volunteers Following Oral Administration of the HIV-1 Protease Inhibitor CGP 53437: Value as Predictor of Antiviral Efficacy. Antivir Chem Chemother 1997. [DOI: 10.1177/095632029700800106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The aim of the study was to determine whether the concentration of CGP 53437 measured in the sera of normal volunteers following oral administration of a single dose, had retained its anti-HIV activity; and whether such results could be of predictive value for future clinical antiviral efficacy studies. CGP 53437 is an inhibitor of HIV-1 protease that suppresses HIV-1 replication in human lymphocytes in vitro at 100 nM. The in vitro anti-HIV activity of human sera obtained from CGP 53437-treated individuals was compared with that of sera spiked with known concentrations of CGP 53437 (in the presence or absence of α-1 acid glycoprotein). It was found that the concentration of the compound measured in the sera from treated individuals provided the expected in vitro anti-HIV activity. These results not only validate our analytical method for detection of CGP 53437, but also support the notion that interaction of CGP 53437 with plasma proteins does not significantly affect its antiviral activity (shift of the ED90 by a factor of three). In conclusion, ex vivo anti-HIV activity determinations of sera containing an HIV protease inhibitor, in conjunction with the pharmacokinetic evaluation during Phase I clinical studies, can provide valuable information regarding the suitability of such inhibitors for further clinical studies.
Collapse
Affiliation(s)
- JK Lazdins
- CIBA Pharma Research, K-125.2.17, CH-4002, Basel, Switzerland
| | - JK Walker
- CIBA Pharma Research, K-125.2.17, CH-4002, Basel, Switzerland
| | - RM Cozens
- CIBA Pharma Research, K-125.2.17, CH-4002, Basel, Switzerland
| | - G Flesch
- CIBA Pharma Research, K-125.2.17, CH-4002, Basel, Switzerland
| | - C Czendlik
- CIBA Pharma Research, K-125.2.17, CH-4002, Basel, Switzerland
| | - H Howald
- CIBA Pharma Research, K-125.2.17, CH-4002, Basel, Switzerland
| | - W Kremers
- CIBA Pharma Research, K-125.2.17, CH-4002, Basel, Switzerland
| | - E Alteri
- CIBA Pharma Research, K-125.2.17, CH-4002, Basel, Switzerland
| |
Collapse
|
16
|
Fässler A, Bold G, Capraro HG, Cozens R, Mestan J, Poncioni B, Rösel J, Tintelnot-Blomley M, Lang M. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability. J Med Chem 1996; 39:3203-16. [PMID: 8759643 DOI: 10.1021/jm960022p] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A series of aza-peptide analogs with a (hydroxyethyl)hydrazine isostere has been synthesized as HIV-1 protease inhibitors using a simple synthetic scheme. Structure-activity studies based on the X-ray of a previously described inhibitor-enzyme complex led to potent inhibitors with antiviral activity in the low-nanomolar range. The S-configuration of the transition-state hydroxyl group was preferred in this series. Small modifications of the P2P3 and P2'P3' substituents had little effect on enzyme inhibition but greatly influenced the pharmacokinetic profile. As a result of these studies, the symmetrically acylated compound 8a and its close analog 24a bearing a methyl carbamate in P3 and an ethyl carbamate in P3' position were identified as potent inhibitors with plasma concentrations exceeding antiviral ED50 values 150-fold following oral application in mice.
Collapse
Affiliation(s)
- A Fässler
- Research Laboratories Cancer and Infectious Diseases, Ciba-Geigy AG, Basel, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
|
18
|
Riese RJ, Wolf PR, Brömme D, Natkin LR, Villadangos JA, Ploegh HL, Chapman HA. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996; 4:357-66. [PMID: 8612130 DOI: 10.1016/s1074-7613(00)80249-6] [Citation(s) in RCA: 423] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Destruction of li by proteolysis is required for MHC class II molecules to bind antigenic peptides, and for transport of the resulting complexes to the cell surface. The cysteine protease cathepsin S is highly expressed in spleen, lymphocytes, monocytes, and other class II-positive cells, and is inducible with interferon-gamma. Specific inhibition of cathepsin S in B lymphoblastoid cells prevented complete proteolysis of li, resulting in accumulation of a class II-associated 13 kDa li fragment in vivo. Consequently, the formation of SDS-stable complexes was markedly reduced. Purified cathepsin S, but not cathepsin B, H, or D, specifically digested li from alpha beta li trimers, generating alpha beta-CLIP complexes capable of binding exogenously added peptide in vitro. Thus, cathepsin S is essential in B cells for effective li proteolysis necessary to render class II molecules competent for binding peptides.
Collapse
Affiliation(s)
- R J Riese
- Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
| | | | | | | | | | | | | |
Collapse
|
19
|
Leroux JC, Cozens R, Roesel JL, Galli B, Kubel F, Doelker E, Gurny R. Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J Pharm Sci 1995; 84:1387-91. [PMID: 8748318 DOI: 10.1002/jps.2600841202] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
CGP 57813 is a peptidomimetic inhibitor of human immunodeficiency virus type 1 (HIV-1) protease. This lipophilic compound was successfully entrapped into poly(D,L-lactic acid) (PLA) and pH sensitive methacrylic acid copolymers nanoparticle. The intravenous administration to mice of PLA nanoparticles loaded with CGP 57813 resulted in a 2-fold increase of the area under the plasma concentration-time curve, compared to a control solution. An increase in the elimination half-life (from 13 to 61 min) and in the apparent volume of distribution (1.7-3.6 L/kg) was observed for the nanoparticle incorporated compound vs control solution. Following oral administration, only nanoparticles made of the methacrylic acid copolymer soluble at low pH provided sufficient plasma levels of CGP 57813. In vitro, these nanoparticles dissolved completely within 5 min at pH 5.8. PLA nanoparticles, which are insoluble in the gastrointestinal tract, did not provide significant plasma concentrations of CGP 57813. From these observations, one can conclude that the passage of intact PLA nanoparticles across the gastrointestinal mucosa appears to be very low.
Collapse
Affiliation(s)
- J C Leroux
- School of Pharmacy, University of Geneva, Switzerland
| | | | | | | | | | | | | |
Collapse
|
20
|
Kempf DJ. Progress in the discovery of orally bioavailable inhibitors of HIV protease. ACTA ACUST UNITED AC 1995. [DOI: 10.1007/bf02172035] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
Billich A, Fricker G, Müller I, Donatsch P, Ettmayer P, Gstach H, Lehr P, Peichl P, Scholz D, Rosenwirth B. SDZ PRI 053, an orally bioavailable human immunodeficiency virus type 1 proteinase inhibitor containing the 2-aminobenzylstatine moiety. Antimicrob Agents Chemother 1995; 39:1406-13. [PMID: 7492076 PMCID: PMC162753 DOI: 10.1128/aac.39.7.1406] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
A series of inhibitors of human immunodeficiency virus type 1 (HIV-1) proteinase containing the 2-aralkyl-amino-substituted statine moiety as a novel transition-state analog was synthesized, with the aim to obtain compounds which combine anti-HIV potency with oral bioavailability. The reduced-size 2-aminobenzylstatine derivative SDZ PRI 053, which contains 2-(S)-amino-3-(R)-hydroxyindane in place of an amino acid amide, is a potent and orally bioavailable inhibitor of HIV-1 replication. The antiviral activity of SDZ PRI 053 was demonstrated in various cell lines, in primary lymphocytes, and in primary monocytes, against laboratory strains as well as clinical HIV-1 isolates (50% effective dose = 0.028 to 0.15 microM). Cell proliferation was impaired only at 100- to 300-fold-higher concentrations. The mechanism of antiviral action of the proteinase inhibitor SDZ PRI 0.53 was demonstrated to be inhibition of gag precursor protein processing. The finding that the inhibitory potency of SDZ PRI 053 in chronic virus infection, determined by p24 release, was considerably lower than that in de novo infection may be explained by the fact that the virus particles produced in the presence of SDZ PRI 053 are about 50-fold less infectious than those from untreated cultures. Upon intravenous administration, half-lives in blood of 100 and 32 min in mice and rats, respectively, were measured. Oral bioavailability of SDZ PRI 053 in rodents was 20 to 60%, depending on the dose. In mice, rats, and dogs, the inhibitor levels after oral administration remained far above the concentrations needed to efficiently block HIV replication in vitro for a prolonged period. This compound is thus a promising candidate for clinical use in HIV disease.
Collapse
Affiliation(s)
- A Billich
- Sandoz Research Institute, Vienna, Austria
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
The proteinase of the human immunodeficiency virus (HIV-1 protease) is an obvious example of a receptor for which drug design methodologies have been successfully applied. In this article, Michael West and David Fairlie outline the specific progress made to date towards the rational design of protease inhibitors as anti-HIV drugs, and compare their pharmacological profiles. The rationale employed in designing protease inhibitors illustrates evolving trends in drug design, problems in comparing assay data, and obstacles to developing enzyme inhibitors into drugs.
Collapse
Affiliation(s)
- M L West
- Centre for Drug Design and Development, University of Queensland, Brisbane, Australia
| | | |
Collapse
|
23
|
Abstract
Biotechnology and the use of biologically based agents for the betterment of mankind is an active field which is founded on the interaction between many basic sciences. This is achieved in coordination with engineering and technology for scaling up purposes. The application of modern recombinant DNA technology gave momentum and new horizons to the field of biotechnology both in the academic setting and in industry. The applications of biotechnology are being used in many fields including agriculture, medicine, industry, marine science and the environment. The final products of biotechnological applications are diverse. In the medical applications of biotechnology, for example, the field has been evolving in such a way that the final product could be a small molecule (e.g. drug/antibiotic) that can be developed based on genetic information by drug design or drug screening using a cloned and expressed target protein.
Collapse
Affiliation(s)
- M R el-Gewely
- Department of Biotechnology, University of Tromsø, Norway
| |
Collapse
|
24
|
Martin JA, Redshaw S, Thomas GJ. Inhibitors of HIV proteinase. PROGRESS IN MEDICINAL CHEMISTRY 1995; 32:239-87. [PMID: 8577919 DOI: 10.1016/s0079-6468(08)70455-7] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- J A Martin
- Roche Products Ltd., Welwyn Garden City, Herts, UK
| | | | | |
Collapse
|
25
|
Billich A, Charpiot B, Fricker G, Gstach H, Lehr P, Peichl P, Scholz D, Rosenwirth B. HIV proteinase inhibitors containing 2-aminobenzylstatine as a novel scissile bond replacement: biochemical and pharmacological characterization. Antiviral Res 1994; 25:215-33. [PMID: 7710270 DOI: 10.1016/0166-3542(94)90005-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Derivation of the 2-aminobenzylstatine containing HIV-1 proteinase (PR) inhibitor I led to a series of compounds with considerably improved antiviral activity, the most potent derivatives inhibiting HIV-1 with IC50 values below 25 nM. This was achieved by the combination of several structural modifications, most prominently by introduction of a benzimidazole heterocycle into the inhibitor. The mode of action of the 2-aminobenzylstatine PR inhibitors was demonstrated to be inhibition of gag precursor processing. The antiviral efficacy of the PR inhibitors was demonstrated in various cell lines, in primary T4 lymphocytes and in monocytes. The most potent compound (XI) inhibited replication of several HIV-1 clinical isolates in primary cells with IC50 values of 8 to 23 nM. The analysis of the pharmacokinetic behaviour of compounds I and VII revealed blood half-lives in rodents in the range of about 1.5 h. Compound I also showed appreciable oral uptake in mice (18%), but yielded no detectable blood levels in rats after oral administration. Benzimidazole containing compounds like VII were not orally bioavailable to a significant extent, neither in mice nor in rats. Thus, while introduction of a benzimidazole group into the PR inhibitors was a successful structural modification with regard to antiviral activity in cell culture, it completely abolished oral bioavailability.
Collapse
Affiliation(s)
- A Billich
- Sandoz Forschungsinstitut, Vienna, Austria
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Flesch G, Mann C, Boss E, Lang M, Degen PH, Dieterle W. Quantitative determination of CGP 53,437, a new HIV protease inhibitor, in plasma by high-performance liquid chromatography and fluorescence detection. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL APPLICATIONS 1994; 657:155-61. [PMID: 7952063 DOI: 10.1016/0378-4347(94)80082-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A specific and sensitive liquid chromatographic assay for CGP 53,437 (I), a potent HIV protease inhibitor, is described. The method is based on a deproteinization step, followed by a liquid-liquid extraction with diisopropyl ether. Then a deprotection step of the primary amine and derivatization using fluorescamine is performed. Chromatography is achieved by isocratic elution with a mobile phase of 63 mM borax buffer (pH 9)-acetonitrile (58:42, v/v). The flow-rate of the mobile phase is 1 ml/min. The derivatives of compound I and its internal standard CGP 54,451, II, fluoresce at 480 nm on excitation at 395 nm. The limit of quantitation which is the lowest concentration of the analyte that can be measured with a coefficient of variation and a deviation from theory of less than 20%, was 5 nmol/l plasma. The analyte is stable for at least seven months in spiked human plasma samples. It is also stable after freezing and thawing cycles. Different human plasma sources and plasma samples from three different species (dog, marmoset, and rat) were tested and no interferences from plasma constituents was observed.
Collapse
Affiliation(s)
- G Flesch
- Ciba-Geigy Ltd, Basle, Switzerland
| | | | | | | | | | | |
Collapse
|
27
|
Chapter 14. HIV Protease Inhibitors. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1994. [DOI: 10.1016/s0065-7743(08)60727-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|
28
|
Lang M, Roesel J. HIV-1 protease inhibitors: development, status, and potential role in the treatment of AIDS. Arch Pharm (Weinheim) 1993; 326:921-4. [PMID: 8122962 DOI: 10.1002/ardp.19933261202] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- M Lang
- Pharmaceuticals Division, CIBA-GEIGY Limited, Basel, Switzerland
| | | |
Collapse
|